The prevalence and expression pattern of melanoma-associated antigen 1 in esophageal squamous cell carcinoma
A historical cohort study
Keywords:
Cancer Testis Antigen, Melanoma-associated antigen 1, Esophageal cancer, Squamous cell carcinomaAbstract
Introduction: Melanoma-associated antigen 1 (MAGE1) expression in normal tissues is restricted to the testes, whilst being over-expressed in a number of human cancers. This feature of MAGE1 makes it a promising cancer biomarker. This study aimed to determine the expression of MAGE1 in esophageal squamous cell carcinoma (SCC) and its relationship with clinicopathological factors.
Methods: This is a cross-sectional study conducted on pretreatment endoscopic tissue specimens of 43 patients with non-metastatic esophageal SCC, admitted to Omid Hospital, Mashhad, Iran, between 2011 and 2013. Out of 127 esophageal SCC patients who had already enrolled in a trial of trimodality therapy, we chose 43 patients whose paraffin blocks of endoscopic samples were accessible, which we then stained for MAGE1 expression by immunohistochemistry. Correlation of MAGE1expression and clinicopathological data (age, sex, stage, grade, and outcome) was assessed using SPSS 16 by T test, chi-square, and Pearson tests (p <0.05 was considered significant).
Results: MAGE1 was expressed in 46.5% (20 out of 43) of esophageal SCC specimens. The MAGE1 nuclear staining increased significantly by age; its expression for <40, 41-49, 50-59, 60-69, and ≥70 years old was 0%, 0%, 8.3%, 26.3%, and 100%, respectively (p=0.02; Person’s R value = 0.3 and p=0.04). There was no significant correlation between MAGE1 expression and other clinicopathological parameters.
Conclusion: MAGE1 antigen has considerable expression in the esophageal SCC among the Iranian population; it can be potentially applied as a cancer biomarker as well as a target for immunotherapy in patients with esophageal SCC.
References
Castro C, Bosetti C, Malvezzi M, Bertuccio P, Levi F, Negri E, et al. Patterns and trends in esophageal
cancer mortality and incidence in Europe (1980–2011) and predictions to 2015. Ann Oncol. 2014; 25(1):
-90. doi: 10.1093/annonc/mdt486. PMID: 24356640.
Anvari K, Aledavood SA, Toussi MS, Forghani MN, Mohtashami S, Rajabi MT, et al. A clinical trial of
neoadjuvant concurrent chemoradiotherapy followed by resection for esophageal carcinoma. J Res Med
Sci. 2015; 20(8): 751-6. doi: 10.4103/1735-1995.168377. PMID: 26664422, PMCID: PMC4652308.
Salek R, Bezenjani SE, Saedi HS, Ashkiki MH, Hosainzade SM, Mohtashami S, et al. A geographic area
with better outcome of esophageal carcinoma: is there an effect of ethnicity and etiologic factors?
Oncology. 2009; 77(3-4): 172-7. doi: 10.1159/000231887. PMID: 19641336.
Nikfarjam Z, Massoudi T, Salehi M, Salehi M, Khoshroo F. Demographic survey of four thousand patients
with 10 common cancers in North Eastern Iran over the past three decades. Asian Pacific journal of cancer
prevention: APJCP. 2014; 15(23): 10193-8. PMID: 25556447.
Iranian Annual of National Cancer Registration Report. Tehran: Ministry of Health and Medical Education,
Center for Disease Control & Prevention, Deputy for Noncommunicable Disease, Cancer Office, 2008.
Prosner MC, Minsky BD, Ilson DH. Cancer of the Esophagus. In: DeVita VT, Lawrence TS, Rosenberg S,
editors. Devita, Hellman, and Rosenberg's Cancer: principles and practice of oncology. 1. 10 ed.
Philadelphia: Lippincott Williams and Wilkins; 2015.
Rustgi AK. Molecular Biology of the Esophagus and Stomach. In: DeVita Jr. VT, Lawrence TS, Rosenberg
SA, editors. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 1. 10 ed.
Philadelphia: Wolters Kluwer; 2015; 570-3.
Woo J, Cohen SA, Grim JE. Targeted therapy in gastroesophageal cancers: past, present and future.
Gastroenterol Rep (Oxf). 2015; 3(4): 316-29. doi: 10.1093/gastro/gov052. PMID: 26510453, PMCID:
PMC4650980.
Posner MC, Minsky BD, Ilson DD. Cancer of the Esophagus. In: DeVita Jr. VT, Lawrence TS, Rosenberg
SA, editors. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 1. 10 ed.
Philadelphia: Wolters Kluwer; 2015; 574-612.
Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy
for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an
international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014; 383(9911): 31-9.
doi: 10.1016/S0140-6736(13)61719-5. PMID: 24094768.
Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T
lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014; 14(2): 135-46. doi:
1038/nrc3670. PMID: 24457417.
Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T
lymphocytes. Annu Rev Immunol. 1994; 12(1): 337-65. doi: 10.1146/annurev.iy.12.040194.002005.
PMID: 8011285.
Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and
cancer. Nat Rev Cancer. 2005; 5(8): 615-25. doi: 10.1038/nrc1669. PMID: 16034368.
Chen YT, Hsu M, Lee P, Shin SJ, Mhawech‐Fauceglia P, Odunsi K, et al. Cancer/testis antigen CT45:
analysis of mRNA and protein expression in human cancer. Int J Cancer. 2009; 124(12): 2893-8. doi:
1002/ijc.24296. PMID: 19296537.
Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci.
; 100(11): 2014-21. doi: 10.1111/j.1349-7006.2009.01303.x. PMID: 19719775.
Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P, et al. Multiple cancer/testis antigens are
preferentially expressed in hormone-receptor negative and high-grade breast cancers. PloS one. 2011; 6(3):
e17876. doi: 10.1371/journal.pone.0017876P. PMID: 21437249, PMCID: PMC3060908.
Dyrskjøt L, Zieger K, Kissow Lildal T, Reinert T, Gruselle O, Coche T, et al. Expression of MAGE-A3,
NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. Br J Cancer. 2012; 107(1): 116-22. doi:
1038/bjc.2012.215. PMID: 22596240, PMCID: PMC3389414.
Haier J, Owzcareck M, Guller U, Spagnoli GC, Bürger H, Senninger N, et al. Expression of MAGE-A
cancer/testis antigens in esophageal squamous cell carcinomas. Anticancer Res. 2006; 26(3B): 2281-7.
PMID: 16821603.
Chen YT, Panarelli NC, Piotti KC, Yantiss RK. Cancer–Testis Antigen Expression in Digestive Tract
Carcinomas: Frequent Expression in Esophageal Squamous Cell Carcinoma and Its Precursor Lesions.
Cancer Immunol Res. 2014; 2(5): 480-6. doi: 10.1158/2326-6066.CIR-13-0124. PMID: 24795360.
Liang Z, Sun ZY, Yuan YH, Han Y, Wang Y, Gu J, et al. [The expression of 11 cancer/testis (CT) antigen
genes in esophageal carcinoma]. Zhonghua Zhong Liu Za Zhia. 2005; 27(9): 534-7. PMID: 16438850.
Bolli M, Schultz‐Thater E, Zajac P, Guller U, Feder C, Sanguedolce F, et al. NY‐ESO‐1/LAGE‐1
coexpression with MAGE‐A cancer/testis antigens: A tissue microarray study. Int J Cancer. 2005; 115(6):
-6. doi: 10.1002/ijc.20953. PMID: 15751033.
Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by
immunohistochemical analysis. M Mod Pathol. 1998; 11(2): 155-68. PMID: 9504686.
Mizukami Y, Kono K, Daigo Y, Takano A, Tsunoda T, Kawaguchi Y, et al. Detection of novel cancer‐
testis antigen‐specific T‐cell responses in TIL, regional lymph nodes, and PBL in patients with
esophageal squamous cell carcinoma. Cancer Sci. 2008; 99(7): 1448-54. doi: 10.1111/j.1349- 7006.2008.00844.x. PMID: 18452554.
Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, et al. Vaccination with multiple
peptides derived from novel cancer‐testis antigens can induce specific T‐cell responses and clinical
responses in advanced esophageal cancer. Cancer Sci. 2009; 100(8): 1502-9. doi: 10.1111/j.1349- 7006.2009.01200.x. PMID: 19459850.
Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen‐A24‐
restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel
targets for immunotherapy. Cancer Sci. 2007; 98(11): 1803-8. doi: 10.1111/j.1349-7006.2007.00603.x.
PMID: 17784873.
Domae S, Ono T, Sasaki A. Cancer/testis antigens: A prospective reagent as diagnostic and
immunotherapeutic targets for squamous cell carcinoma of the head and neck. Japanese Dental Science
Review. 2014; 50(4): 91-9. doi: 10.1016/j.jdsr.2014.06.001.
Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S, et al. Immunogenic tumor cell
death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res.
; 72(16): 3967-76. doi: 10.1158/0008-5472.CAN-12-0851. PMID: 22700877.
Toh U, Sasada T, Takahashi R, Itoh K, Akagi Y. Tumor Immunotherapy of Esophageal and Gastric
Cancers. Cancer Immunology: Springer; 2015; 185-97.
Forghanifard MM, Gholamin M, Farshchian M, Moaven O, Memar B, Forghani MN, et al. Cancer-testis
gene expression profiling in esophageal squamous cell carcinoma: identification of specific tumor marker
and potential targets for immunotherapy. Cancer Biol Ther. 2011; 12(3): 191-7. doi:
4161/cbt.12.3.15949. PMID: 21613820.
Akcakanat A, Kanda T, Tanabe T, Komukai S, Yajima K, Nakagawa S, et al. Heterogeneous expression of
GAGE, NY ‐ ESO ‐ 1, MAGE ‐ A and SSX proteins in esophageal cancer: Implications for
immunotherapy. Int J Cancer. 2006; 118(1): 123-8. doi: 10.1002/ijc.21219. PMID: 16003736.
Kinugasa S, Tachibana M, Yoshimura H, Dhar DK, Shibakita M, Ohno S, et al. Esophageal resection in
elderly esophageal carcinoma patients: improvement in postoperative complications. The Annals of
Thoracic Surgery. 2001; 71(2): 414-8. doi: 10.1016/S0003-4975(00)02333-X. PMID: 11235680.
Kavalar R, Sarcevic B, Spagnoli GC, Separovic V, Samija M, Terracciano L, et al. Expression of MAGE
tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast
cancers: an immunohistochemical study. Virchows Arch. 2001; 439(2): 127-31. doi:
1007/s004280100421. PMID: 11561752.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
